Literature DB >> 27021296

CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis.

Jie Li1, Sara McArdle1, Amin Gholami1, Takayuki Kimura1, Dennis Wolf1, Teresa Gerhardt1, Jacqueline Miller1, Christian Weber1, Klaus Ley2.   

Abstract

RATIONALE: CD4 T cells are involved in the pathogenesis of atherosclerosis, but atherosclerosis-specific CD4 T cells have not been described. Moreover, the chemokine(s) that regulates T-cell trafficking to the atherosclerotic lesions is also unknown.
OBJECTIVE: In Apoe(-/-) mice with mature atherosclerotic lesions (5 months of high fat diet), we find that most aortic T cells express CCR5 and interferon-γ with a unique combination of cell surface markers (CD4(+)CD25(-)CD44(hi)CD62L(lo)) and transcription factors (FoxP3(+)T-bet(+)). We call these cells CCR5Teff. We investigated the role of CCR5 in regulating T-cell homing to the atherosclerotic aorta and the functionality of the CCR5Teff cells. METHODS AND
RESULTS: CCR5Teff cells are exclusively found in the aorta and para-aortic lymph nodes of Apoe(-/-) mice. They do not suppress T-cell proliferation in vitro and are less potent than regulatory T cells at inhibiting cytokine secretion. Blocking or knocking out CCR5 or its ligand CCL5 significantly blocks T-cell homing to atherosclerotic aortas. Transcriptomic analysis shows that CCR5Teff cells are more similar to effector T cells than to regulatory T cells. They secrete interferon-γ, interleukin-2, interleukin-10, and tumor necrosis factor. Adoptive transfer of these CCR5Teff cells significantly increases atherosclerosis.
CONCLUSIONS: CCR5 is specifically needed for CD4 T-cell homing to the atherosclerotic plaques. CCR5(+)CD4 T cells express an unusual combination of transcription factors, FoxP3 and T-bet. Although CCR5Teff express FoxP3, we showed that they are not regulatory and adoptive transfer of these cells exacerbates atherosclerosis.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  CCR5 protein, mouse; Ccl5 protein, mouse; Treg cells; atherosclerosis; chemokines; inflammation; vascular diseases

Mesh:

Substances:

Year:  2016        PMID: 27021296      PMCID: PMC4867125          DOI: 10.1161/CIRCRESAHA.116.308648

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  71 in total

1.  Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression.

Authors:  S E Roselaar; P X Kakkanathu; A Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

2.  CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall.

Authors:  Elena Galkina; Brian L Harry; Andreas Ludwig; Elisa A Liehn; John M Sanders; Anthony Bruce; Christian Weber; Klaus Ley
Journal:  Circulation       Date:  2007-10-01       Impact factor: 29.690

3.  Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice.

Authors:  R Elhage; A Maret; M T Pieraggi; J C Thiers; J F Arnal; F Bayard
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

4.  Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis.

Authors:  C Weber; R Alon; B Moser; T A Springer
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

5.  A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice.

Authors:  Vincent Braunersreuther; Sabine Steffens; Claire Arnaud; Graziano Pelli; Fabienne Burger; Amanda Proudfoot; François Mach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-03       Impact factor: 8.311

6.  Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.

Authors:  Christophe Combadière; Stéphane Potteaux; Mathieu Rodero; Tabassome Simon; Adeline Pezard; Bruno Esposito; Régine Merval; Amanda Proudfoot; Alain Tedgui; Ziad Mallat
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 7.  Interferon gamma: a master regulator of atherosclerosis.

Authors:  James E McLaren; Dipak P Ramji
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-28       Impact factor: 7.638

8.  Endotoxin augmented antigen-induced Th1 cell trafficking amplifies airway neutrophilic inflammation.

Authors:  Zamaneh Mikhak; Alireza Farsidjani; Andrew D Luster
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.

Authors:  Maha Ayyoub; Florence Deknuydt; Isabelle Raimbaud; Christelle Dousset; Lucie Leveque; Gilles Bioley; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

10.  TopHat: discovering splice junctions with RNA-Seq.

Authors:  Cole Trapnell; Lior Pachter; Steven L Salzberg
Journal:  Bioinformatics       Date:  2009-03-16       Impact factor: 6.937

View more
  50 in total

1.  Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.

Authors:  Takayuki Kimura; Kevin Tse; Sara McArdle; Teresa Gerhardt; Jacqueline Miller; Zbigniew Mikulski; John Sidney; Alessandro Sette; Dennis Wolf; Klaus Ley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-13       Impact factor: 4.733

Review 2.  Single Cell RNA Sequencing in Atherosclerosis Research.

Authors:  Jesse W Williams; Holger Winkels; Christopher P Durant; Konstantin Zaitsev; Yanal Ghosheh; Klaus Ley
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 3.  Autoimmunity and organ damage in systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  Nat Immunol       Date:  2020-05-04       Impact factor: 25.606

Review 4.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

5.  [Immunity and inflammation in atherosclerosis].

Authors:  D Wolf; K Ley
Journal:  Herz       Date:  2019-04       Impact factor: 1.443

Review 6.  ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.

Authors:  Klaus Ley; Norbert Gerdes; Holger Winkels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-30       Impact factor: 8.311

Review 7.  Vascular Endothelial Cells and Innate Immunity.

Authors:  Ying Shao; Jason Saredy; William Y Yang; Yu Sun; Yifan Lu; Fatma Saaoud; Charles Drummer; Candice Johnson; Keman Xu; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-05-27       Impact factor: 8.311

Review 8.  Atherosclerosis in the single-cell era.

Authors:  Holger Winkels; Erik Ehinger; Yanal Ghosheh; Dennis Wolf; Klaus Ley
Journal:  Curr Opin Lipidol       Date:  2018-10       Impact factor: 4.776

9.  Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry.

Authors:  Holger Winkels; Erik Ehinger; Melanie Vassallo; Konrad Buscher; Huy Q Dinh; Kouji Kobiyama; Anouk A J Hamers; Clément Cochain; Ehsan Vafadarnejad; Antoine-Emmanuel Saliba; Alma Zernecke; Akula Bala Pramod; Amlan K Ghosh; Nathaly Anto Michel; Natalie Hoppe; Ingo Hilgendorf; Andreas Zirlik; Catherine C Hedrick; Klaus Ley; Dennis Wolf
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

Review 10.  Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas.

Authors:  Alma Zernecke; Holger Winkels; Clément Cochain; Jesse W Williams; Dennis Wolf; Oliver Soehnlein; Clint S Robbins; Claudia Monaco; Inhye Park; Coleen A McNamara; Christoph J Binder; Myron I Cybulsky; Corey A Scipione; Catherine C Hedrick; Elena V Galkina; Tin Kyaw; Yanal Ghosheh; Huy Q Dinh; Klaus Ley
Journal:  Circ Res       Date:  2020-07-16       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.